TISSUE BIOBANKING AND PROCESSING SHARED RESOURCE (Core-745) ABSTRACT Overview: The Tissue Biobanking and Processing Shared Resource (TBPSR) supports translational and clinical research projects of UCCC members by providing access to high-quality tissue and body fluid specimens that are associated with clinicopathologic and outcomes data. Equipment: The TBPSR has a wide variety of state of the art equipment for the procurement, processing, storage, and analysis of biospecimens. Services: The TBPSR provides services in three main areas 1) procurement, processing, archiving, and distribution of fresh and formalin-fixed tissues and body fluids, 2) specimen characterization, quality control, and linkage with pathological and clinical annotation, 3) special processing and auxiliary services including tissue microarray construction, laser capture microdissection and computer-assisted imaging/ image analysis. The TBPSR collaborates with the Cancer Clinical Trial Office and Health Data Compass to provide consents and detailed clinical and pathologic data correlated with distributed specimens. Consultation and Education: The TBPSR directors and staff consult with UCCC members to discuss protocol, project and grant development. The TBPSR directors provide educational sessions on biorepository and specimen management to researchers, students, and clinicians. Management: The TBPSR is a division of the larger Biorepository Core Facility, an institutional core managed by the institution. TBPSR is overseen by UCCC Associate Director for Population Sciences Research. Use of Services: Over the current funding period 64 UCCC members have used the services, representing all 6 Programs and resulting in 55 peer reviewed publications. CCSG funding represents 7% of the annual operating budget. The remaining support comes from the CCTSI grant (6%), other peer-reviewed grants (61%), institutional support (13%) and user fees (13%). Future Directions: The TBPSR proposes the following initiatives that will enhance the SR and UCCC member cancer research: 1) Implement the iLab system for management of the TBPSR; 2) Expand integration with the Health Data Compass. Compass is an integrated enterprise health data warehouse of all patient data obtained from consortium institutions (UCD, UCH, CHCO) which also provides analytic services designed to transform data-driven processes in clinical research, molecular discovery, and precision medicine; 3) Integrate with the Oncology Research Information Exchange Network (ORIEN), a consortium of academic medical centers utilizing a common protocol for tracking patient molecular, clinical and epidemiological data that follows the patient throughout his or her lifetime. This will expand the scope of the TBPSR locally and also help advance cancer research and care nationally.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-33
Application #
10133548
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-04
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
33
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236
Sanchez, Gilson J; Richmond, Phillip A; Bunker, Eric N et al. (2018) Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res 46:1756-1776
Witt, Davis A; Donson, Andrew M; Amani, Vladimir et al. (2018) Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer 65:e26960
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Lyu, Hui; Wang, Shuiliang; Huang, Jingcao et al. (2018) Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. Cancer Lett 420:97-108
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
Guarnieri, A L; Towers, C G; Drasin, D J et al. (2018) The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene 37:3879-3893
Radakovich, Lauren B; Marolf, Angela J; Shannon, John P et al. (2018) Development of a microcomputed tomography scoring system to characterize disease progression in the Hartley guinea pig model of spontaneous osteoarthritis. Connect Tissue Res 59:523-533
Wu, Xiaorong; An, Xiuxiang; Zhang, Caiguo et al. (2018) Clb6-Cdc28 Promotes Ribonucleotide Reductase Subcellular Redistribution during S Phase. Mol Cell Biol 38:

Showing the most recent 10 out of 1634 publications